Systemic inflammatory pathways

Systemic inflammatory pathways encompass the integrated network of signaling cascades and molecular mediators that regulate the body's immune response to harmful stimuli, such as pathogens or tissue damage (StatPearls, 2023). These pathways are characterized by the production and release of pro-inflammatory cytokines, such as Tumor necrosis factor-alpha (TNF-α) and Interleukin-6 (IL-6), and the activation of intracellular signaling routes like the NF-κB and JAK-STAT pathways (PubMed, PMID: 29403023). While these processes are vital for host defense, their dysregulation can lead to systemic inflammatory response syndrome (SIRS), sepsis, or chronic inflammatory states associated with cardiovascular and metabolic diseases (NIH, 2022). Therapeutic strategies often target specific components of these pathways, such as using monoclonal antibodies to neutralize cytokines or small molecules to inhibit Janus kinases, thereby dampening the inflammatory cascade (Nature Reviews Drug Discovery, 2017). However, broad or prolonged inhibition of these pathways carries significant risks, including increased vulnerability to infections and impaired tissue repair (PubMed, PMID: 30272097).

Other names

Systemic inflammationInflammatory signaling cascadesChronic systemic inflammationSystemic inflammatory response syndrome pathways

Drugs targeting these pathways typically act by neutralizing circulating pro-inflammatory cytokines, blocking their respective cell-surface receptors, or inhibiting downstream intracellular signaling kinases to prevent the transcription of inflammatory genes (Nature Reviews Drug Discovery, 2017).